Add BrightSurf on Google Email

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateJun 4, 2023

Journal of Clinical Immunology publishes Octapharma USA research on cutaquig® evaluating PI treatment options

A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.

SourceYankee Public Relations·JournalJournal of Clinical Immunology·TypeObservational study·DateMay 18, 2023

International panel led by RCSI Professor classifies immunotherapy side effects for the first time

An international panel of experts has developed standardized definitions for immunotherapy side effects, providing a shared vocabulary for clinicians to standardize clinical practice guidelines. This will help support clinicians in offering the best treatment to patients and enable research into biomarkers predicting adverse effects.

SourceRCSI·JournalJournal for ImmunoTherapy of Cancer·DateApr 4, 2023

New details on how immune cells ‘see’ and respond to mutations in cancer cells may lead to more targeted and effective immunotherapy

A new study has identified the steps by which immune cells recognize and respond to cancer cell mutations, providing insights into why some treatments work for certain patients but not others. Researchers believe their findings will lead to better, more personalized immunotherapies for patients whose immune systems currently do not app...

SourceUniversity of California - Los Angeles Health Sciences·JournalNature·TypeExperimental study·DateMar 8, 2023

Molecular machines could treat fungal infections

Researchers at Rice University have developed light-activated nanoscale drills that can kill pathogenic fungi, providing a potential new treatment option for fungal infections. The molecular machines target the mitochondria of fungal cells, disrupting cellular metabolism and leading to cell death.

SourceRice University·JournalAdvanced Science·TypeExperimental study·DateFeb 1, 2023

Clinical trial shows boiled peanuts could help overcome child peanut allergy

A clinical trial found that boiling peanuts for up to 12 hours can desensitize children with peanut allergies. The therapy involved sequential doses of boiled and roasted peanuts, achieving high success rates in participants. While promising, the study's findings require confirmation in larger trials.

SourceFlinders University·JournalClinical & Experimental Allergy·TypeRandomized controlled/clinical trial·DateJan 11, 2023

Can boiled peanuts help cure peanut allergies?

A phase 2 clinical trial using boiled peanuts followed by roasted peanuts showed promising results in desensitizing 80% of children with peanut allergies. Treatment-related adverse events were reported in 61% participants.

SourceWiley·JournalClinical & Experimental Allergy·DateJan 11, 2023

Cellular messengers improve cancer therapy

Extracellular vesicles from immune cells have been shown to activate the immune system in mice with skin cancer, rendering them sensitive to checkpoint inhibitor therapy. The treatment improved survival rates when used in combination with checkpoint inhibitors.

SourceKarolinska Institutet·JournalCancer Immunology Research·TypeExperimental study·DateDec 22, 2022

Albert Einstein College of Medicine researchers develop promising new cancer therapy

Scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy by using natural killer (NK) cells. The research team developed a monoclonal antibody targeting KIR2DL5, which allowed NK cells to vigorously attack and shrink human tumors.

SourceAlbert Einstein College of Medicine·JournalJournal of Clinical Investigation·TypeExperimental study·DateNov 15, 2022

Sugar molecules as a target in cancer therapy

Researchers report a promising new approach that involves altering sugar molecules on the surface of cancer cells in mice, leading to a significant increase in anti-tumor immune response. The study focuses on sialic acid sugars, which are also present on healthy cells and play a role in cell-to-cell communication.

SourceUniversity of Basel·JournalScience Translational Medicine·DateNov 7, 2022

Cancer patients treated with immunotherapy can safely receive mRNA COVID-19 vaccines, according to JNCCN study

Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateOct 17, 2022

Stowers scientists use zebrafish to understand the connection between the immune system and regeneration

Stowers scientists investigate macrophage activation states in zebrafish sensory organ, discovering three distinct anti-inflammatory pathways that may inform human regenerative immunotherapies. The study provides valuable insights into the timing and genetic programs of macrophages, a type of white blood cell, in repair and regeneration.

SourceStowers Institute for Medical Research·JournalNature Communications·TypeExperimental study·DateSep 20, 2022

Immunotherapy reduces lung and liver fibrosis in mice

Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.

SourceUniversity of Zurich·JournalCell Stem Cell·TypeExperimental study·DateSep 15, 2022

Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses

A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.

Immunotherapy before surgery induces complete response in more than half of patients with common skin cancer in international study

In an international clinical trial, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery. The anti-PD1 therapy cemiplimab was well-tolerated and met its primary endpoint with a pathologic complete response rate of 50.6%.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNew England Journal of Medicine·DateSep 12, 2022

University of Cincinnati study: Immunotherapy drug did not increase surgery complications

Researchers conducted a study on administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer and found no increased rates of complications during and after surgery. The findings are encouraging for patients who have not previously received treatment for their oral cavity cancer, suggesting that complication rat...

SourceUniversity of Cincinnati·JournalJAMA·TypeObservational study·DateSep 7, 2022

Researchers discover potential new melanoma treatment giving hope to patients

A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.

SourceHunter Medical Research Institute·JournalCancer Research Communications·TypeRandomized controlled/clinical trial·DateSep 5, 2022

‘Drug factory’ implants eliminate mesothelioma tumors in mice

Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.

SourceRice University·JournalClinical Cancer Research·TypeExperimental study·DateAug 22, 2022

Researchers developed a small molecule that makes immunotherapy available to all cancer patients

Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.

SourceTel-Aviv University·JournalJournal for ImmunoTherapy of Cancer·DateAug 8, 2022

Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.

SourceUniversity of Pittsburgh·JournalScience Immunology·TypeExperimental study·DateAug 5, 2022

Oncotarget | Predicting cancer immunotherapy response from gut microbiomes using machine learning models

A new study uses machine learning models to predict cancer patients' responses to immunotherapy based on their gut microbiome features. The research identifies common gut bacterial taxa associated with responders versus non-responders, providing a potential tool for distinguishing and predicting immunotherapy responders.

SourceImpact Journals LLC·JournalOncotarget·TypeComputational simulation/modeling·DateJul 19, 2022